Albus Health’s CEO, Mikesh Udani, explains to Diana Andrade of Clinical Trial Vanguard, how the company’s passive, contactless bedside device is reshaping what clinical trials can measure at home by prioritizing privacy from the outset. The system captures sleep, respiratory metrics, cough and other symptoms without wearables or patient effort, enabling long‑term, clinically accurate monitoring that was previously only possible in sleep labs—crucial for paediatrics, rare diseases, oncology and chronic conditions where nighttime symptoms signal deterioration or treatment response.

Udani emphasises that privacy‑by‑design is both an ethical foundation and a commercial differentiator: Albus collects only anonymised symptom data, meets stringent global regulatory standards, and consistently earns high patient trust. This combination of passive monitoring, rigorous data protection and patient‑centred design is allowing pharma sponsors to run more inclusive, lower‑burden, higher‑quality trials across more than 40 countries.

Read the full article here.